The Effects of a2 Infant Formula on Growth and Tolerance in Healthy Term Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-14

Study Completion Date

2023-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open-label, prospective study to evaluate the nutritive effects of an a2 infant formula on growth and tolerance in healthy term infants. A total of 280 healthy, term, mixed-fed infants between 60 and 120 days of age were enrolled at Shanghai. The participants were randomly assigned to one of the two study groups: the a2 infant formula group and the conventional A1/A2 infant formula group. Each group contained 140 infants. The study duration was 56 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Infant Formula-fed

NCT02621814

Body Weight Changes

COMPLETED NA

Comparative Effects of A2 Platinum Stage 1 Infant Formula on Infant Digestion and Comfort

NCT04733937

Healthy Infants

COMPLETED NA

Comparative A1 vs A2 Formula and Breast Feeding on Alimentation and Gastrointestinal Digestion for the Infant

NCT03081936

Intestinal Absorption

COMPLETED PHASE4

Clinical Trial of Infant Formula-fed

NCT02715895

Body Weight Changes

UNKNOWN NA

Growth and Metabolic Biomarkers of Healthy Term Infants Fed Formulas With Staged Protein Concentrations Over the First Year of Life

NCT02646969

Healthy Term Infants

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective:

To compare the growth measurements of the infants fed with the a2 infant formula with those fed with conventional A1/A2 infant formula during the study period.

Secondary objectives:

To compare the two study groups in

1. Dermatitis quality of life
2. Formula tolerability and acceptability
3. All medically confirmed adverse events

The study included four visits at day 0 (baseline), day 14, day 28 and day 56. Information of efficacy outcomes were collected at each visit. Subject diary was used to record tolerance data and daily formula feeding amount during the study. The parents of the participants were also required evaluate their satisfaction with the study formula at the last visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

a2 Platinum Premium Infant Formula Stage 1

a2 Platinum Premium Stage 1 (0-6 months) cow's milk based powder infant formula

Group Type EXPERIMENTAL

a2 Platinum Premium Infant Formula Stage 1

Intervention Type DIETARY_SUPPLEMENT

Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)

Frisolac Infant Formula Stage 1 (Dutch Edition)

Dutch Edition of the Frisolac Stage 1 (0-6 months) cow's milk based powder infant formula

Group Type ACTIVE_COMPARATOR

Frisolac Infant Formula Stage 1 (Dutch Edition)

Intervention Type DIETARY_SUPPLEMENT

Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

a2 Platinum Premium Infant Formula Stage 1

Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)

Intervention Type DIETARY_SUPPLEMENT

Frisolac Infant Formula Stage 1 (Dutch Edition)

Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy and term infants (37-42 weeks gestation);
* Birth weight between 2500g and 4500g;
* 60-120 days of age after birth;
* Mixed-fed: Infants who were fed with a mixture of formula and human milk, and received daily formula consumption of more than 400ml;
* Signed informed consent obtained form the guardian(s) of the infants;
* Parent or guardian of infant agrees not to enroll infant in another interventional clinical research survey while participating in this survey.

Exclusion Criteria

* Congenital anomaly or hereditary/chronic/congenital diseases that could interfere with the study product evaluations;
* Evidence of feeding difficulties or intolerance/allergy to cow's milk;
* Conditions requiring infant feedings other than those specified in the protocol;
* Significant systemic disorders (cardiac, respiratory, endocrinological, hematologic, gastrointestinal, or other) or parental refusal to participate;
* Acute infection or gastroenteritis at the time of enrollment;
* Participation in other clinical trials at the time of the study;
* Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.

Minimum Eligible Age

60 Days

Maximum Eligible Age

120 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes